Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NYSE - Nasdaq Real Time Price USD

Zoetis Inc. (ZTS)

Compare
163.11
-1.91
(-1.16%)
At close: March 28 at 4:00:02 PM EDT
164.33
+1.22
+(0.75%)
After hours: March 28 at 6:02:42 PM EDT
Loading Chart for ZTS
  • Previous Close 165.02
  • Open 164.00
  • Bid --
  • Ask --
  • Day's Range 162.83 - 165.40
  • 52 Week Range 144.80 - 200.33
  • Volume 1,478,575
  • Avg. Volume 3,012,700
  • Market Cap (intraday) 73.039B
  • Beta (5Y Monthly) 0.94
  • PE Ratio (TTM) 29.87
  • EPS (TTM) 5.46
  • Earnings Date May 6, 2025
  • Forward Dividend & Yield 2.00 (1.23%)
  • Ex-Dividend Date Apr 21, 2025
  • 1y Target Est 199.99

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.

www.zoetis.com

13,800

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ZTS

View More

Performance Overview: ZTS

Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ZTS
0.41%
S&P 500 (^GSPC)
5.11%

1-Year Return

ZTS
2.58%
S&P 500 (^GSPC)
6.22%

3-Year Return

ZTS
11.45%
S&P 500 (^GSPC)
21.97%

5-Year Return

ZTS
51.74%
S&P 500 (^GSPC)
119.59%

Compare To: ZTS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ZTS

View More

Valuation Measures

Annual
As of 3/28/2025
  • Market Cap

    73.04B

  • Enterprise Value

    77.80B

  • Trailing P/E

    29.82

  • Forward P/E

    27.10

  • PEG Ratio (5yr expected)

    2.88

  • Price/Sales (ttm)

    8.02

  • Price/Book (mrq)

    15.31

  • Enterprise Value/Revenue

    8.41

  • Enterprise Value/EBITDA

    20.18

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    26.86%

  • Return on Assets (ttm)

    14.87%

  • Return on Equity (ttm)

    51.14%

  • Revenue (ttm)

    9.26B

  • Net Income Avi to Common (ttm)

    2.49B

  • Diluted EPS (ttm)

    5.46

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.99B

  • Total Debt/Equity (mrq)

    143.17%

  • Levered Free Cash Flow (ttm)

    2.37B

Research Analysis: ZTS

View More

Company Insights: ZTS

Research Reports: ZTS

View More

People Also Watch